Results · Apr-Jun 2026
Windlas Biotech Q1 FY27 results
Sales grew 18% to ₹248 crore from ₹210 crore in Apr-Jun 2025.
Operating profit grew 1% to ₹26.7 crore, an operating margin of 10.8% (down 1.9 points from a year ago).
Net profit was flat at ₹17.7 crore against Apr-Jun 2025.
Against Jan-Mar 2026: sales +4%, net profit +10%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 248.1 | 210.1 | +18% |
| Operating profit (EBITDA) | 26.7 | 26.5 | +1% |
| Operating margin | 10.8% | 12.6% | −1.9 pts |
| Net profit | 17.7 | 17.7 | −0% |
Standalone figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.